<DOC>
	<DOCNO>NCT00800982</DOCNO>
	<brief_summary>This single-center , open-label , pilot study . A total 30 subject ( 15 study arm ) enrol 6 month study evaluate whether addition narrow band UVB ( NB-UVB ) phototherapy enhance efficacy etanercept 's maintenance dose , 50 mg week , obese psoriasis patient .</brief_summary>
	<brief_title>Open Label Study Etanercept 's Maintenance Dose Obese Patients With Moderate Severe Plaque Type Psoriasis</brief_title>
	<detailed_description>In Phase I , subject receive etanercept 's induction dose , 50 mg twice week , total 12 week . In Phase II , subject receive etanercept 's maintenance dose , 50 mg week , Weeks 12-24 . Those subject randomize treatment arm receive NB-UVB phototherapy 3 time week Phase II . In order ensure homogeneity NB-UVB arm non-NB-UVB arm , subject randomize accord Body Mass Index ( BMI ) . The Psoriasis Area Severity Index ( PASI ) score Physician Global Assessment ( PGA ) calculate visit determine effectiveness etanercept NB-UVB treatment phase study . The hypothesis combination NB-UVB phototherapy three time week etanercept maintenance dose ( 50 mg week ) enhance efficacy maintenance dose alone obese patient ( BMI &gt; 30 ) moderate severe psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Nonimmunocompromised male females 18 year age old . Must able read , understand , speak basic English . Body Surface Area ( BSA ) involvement great 10 % . Psoriasis Area Severity Index great 10 . Obese define Body Mass Index great 30 . Eligible systemic therapy , particularly etanercept , Narrow Band Ultraviolet B opinion investigator . Sign date appropriate write informed consent Health Insurance Portability Accountability Act authorization Negative urine pregnancy test within 7 day first dose etanercept woman ( except surgically sterile least 5 year postmenopausal ) . No evidence active latent tuberculosis base negative Purified Protein Derivative skin test . Patients documentation adequately treat tuberculosis may enrol . Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study . Willing able selfadminister subcutaneous injection qualify person available administer subcutaneous injection Agrees comply protocol requirement , attend regularly study visit consider good study subject Meets concomitant medication washout requirement Erythrodermic , pustular , guttate psoriasis Evidence skin condition psoriasis would interfere studyrelated evaluation psoriasis . Known sensitivity component study medication . Evidence active infection fever , chill , sweat , history untreated Lyme disease active severe infection within 4 week screen visit , screen Week 0 visit . Evidence latent active hepatitis B infection indicate positive HBsAg test screen visit . Personal first degree family history neurologic disease . Poorly control medical condition include , limited , unstable cardiovascular disease , poorly control diabetes , recent stroke , history recurrent infection , condition , opinion investigator , participation study would place subject risk . History Tumor Necrosis FactorÎ± inhibitor use include etanercept , infliximab , adalimumab within 4 week start study drug . History noncutaneous malignancy within past 5 year . History drug alcohol abuse . Substance abuse must clearly documented patient remote minor history drug/alcohol use still opportunity participate study . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . Plans receive live vaccine study . Evidence photosensitivity disorder ( i.e . polymorphous light eruption ) . Known photosensitivity know sensitivity excipients product administer dose . Current enrollment another clinical study treatment another experimental drug approve therapy experimental use within 30 day prior Week 0 Can commit assessment require protocol Any disorder compromise ability subject give write informed consent and/or comply study procedure Considered investigator , reason , unsuitable candidate study participation . Can wish comply protocol washout requirement ( please see section entitle `` Washout Period Prior Week 0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Obese patient ( BMI &gt; 30 )</keyword>
	<keyword>Patients moderate severe psoriasis</keyword>
</DOC>